EuBiologics secures 10.1B KRW cholera vaccine contract
유바이오로직스
206650
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=772
Risk-adjusted indicator based on 772 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
POSITIVE
Key Numbers
- • Contract Amount: 10,102,165,989 KRW (USD 6,737,023)
- • Percentage of Recent Revenue: 6.77%
- • Recent Annual Revenue (2025): 149,195,024,704 KRW
- • Contract Period: July 13, 2026 - September 12, 2026
AI Analysis Summary
EuBiologics Co., Ltd. announced a contract with UNICEF for the supply of oral cholera vaccine (Euvichol-S) valued at 10,102,165,989 KRW (USD 6,737,023). This contract represents 6.77% of the company's recent annual revenue (2025: 149,195,024,704 KRW). The supply is for the Democratic Republic of Congo, with the contract period from July 13, 2026, to September 12, 2026. This recurring contract with UNICEF is a positive for revenue stability.
How This Event Is Evaluated
Strategic Contract Evaluation
Contract events are evaluated by measuring business scale, revenue relevance, counterparty quality, and execution visibility.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Contract size relative to company revenue
- Expected revenue impact
- Counterparty quality
- Contract duration and execution period
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.